Progressive multiple sclerosis: pathology and pathogenesis (Q38046113)

27 August 2017

title

Progressive multiple sclerosis: pathology and pathogenesis (English)

1 reference

27 August 2017

0 references

0 references

0 references

1

1 reference

27 August 2017

2

Jack van Horssen

1 reference

27 August 2017

Don Mahad

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

25 September 2012

1 reference

27 August 2017

published in

Nature Reviews Neurology

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

647-656

1 reference

The immunopathology of multiple sclerosis: an overview

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Defining the clinical course of multiple sclerosis: Results of an international survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Multiple sclerosis: an immune or neurodegenerative disorder?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Control of microglial neurotoxicity by the fractalkine receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

PD-1 regulates neural damage in oligodendroglia-induced inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Clinical demographics of multiplex families with multiple sclerosis. Multiple Sclerosis Genetics Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Relapses and progression of disability in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Evidence for a two-stage disability progression in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Age at disability milestones in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Genetic variants of Complex I in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Clonal expansions of CD8( ) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Multiple sclerosis: distribution of inflammatory cells in newly forming lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Multiple sclerosis: serial study of gadolinium-enhanced MR imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal damage in acute multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal Transection in the Lesions of Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal pathology in multiple sclerosis. A historical note

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Thalamic neurodegeneration in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Inflammatory cortical demyelination in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Pathological abnormalities in the normal-appearing white matter in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Neocortical neuronal, synaptic, and glial loss in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

General mechanisms of axonal damage and its prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Cutting edge: Multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Neurofascin as a novel target for autoantibody-mediated axonal injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Review: The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Immunopathology of secondary-progressive multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Remyelination in the CNS: from biology to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Taking ageing into account in remyelination-based therapies for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

The yin and yang of microglia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal protection in multiple sclerosis--a particular need during remyelination?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Review: Mitochondria and disease progression in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Mitochondrial defects in acute multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Mitochondrial changes within axons in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Enhanced number and activity of mitochondria in multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Axonal protection achieved in a model of multiple sclerosis using lamotrigine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

How mitochondria produce reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Advances in metal-induced oxidative stress and human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Peroxynitrite formation within the central nervous system in active multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Elevated myeloperoxidase activity in white matter in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Radical changes in multiple sclerosis pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Oxidative damage in multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

The effect of age on the non-haemin iron in the human brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Cytokine toxicity to oligodendrocyte precursors is mediated by iron

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Neuroprotective strategies involving ROS in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Roles of oxidative stress, apoptosis, PGC-1α and mitochondrial biogenesis in cerebral ischemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

R pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

The prospects of minocycline in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Multiple sclerosis. Pathology of recurrent lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Demyelination versus remyelination in progressive multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Remyelination is extensive in a subset of multiple sclerosis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Remyelination in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2012.168

Demyelination: the role of reactive oxygen and nitrogen species

31 March 2020

1 reference

12 December 2020

Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein

1 reference

12 December 2020

Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis

1 reference

12 December 2020

Oxidative stress in brain ischemia.

1 reference

12 December 2020

Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions

1 reference

12 December 2020

Iron deposits surrounding multiple sclerosis plaques.

1 reference

12 December 2020

Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.

1 reference

12 December 2020

NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury

1 reference

12 December 2020

Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients

1 reference

12 December 2020

10.1038/NRNEUROL.2012.168

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1014741291

0 references

1 reference